Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Role of immune dysfunction in Moyamoya disease - LCM proteomics

ABSTRACT: Moyamoya disease (MMD) is a rare and progressive cerebrovascular disorder characterized by the gradual stenosis (narrowing) and occlusion of critical intracranial arteries. The etiology of this disease is still unknown. Here we use Laser capture microdissection followed by shotgun proteomics to analyse the brain of a moyamoya patient. We found that phenotypic switching of VSMCs may be involved in the occlusion of the arteries. In addition, invasion of immune cells such as macrophages, in the occluding tissue were found, strengthening the hypothesis that an abberant immune response to infection may be one of the key mechanisms in MMD pathology.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Brain

DISEASE(S): Moyamoya Disease

SUBMITTER: Patrick Willems

LAB HEAD: Francis Impens

PROVIDER: PXD057183 | Pride | 2025-10-20

REPOSITORIES: Pride

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	DIA-NN_1.9_output.zip	Other
	SampleInfo.xlsx	Xlsx
	T063417_AurEl7_PM7_CMB-1515_9_GD6_1_10072.d.zip	Other
	T063423_AurEl7_PM7_CMB-1515_6_GD3_1_10078.d.zip	Other
	T063425_AurEl7_PM7_CMB-1515_5_GD2_1_10080.d.zip	Other

Items per page:

1 - 5 of 11

Similar Datasets

Plasma proteomics moyamoya disease

Project description:Moyamoya disease is a rare cerebrovascular disorder characterized by progressive stenosis of large intracranial arteries and a secondary compensatory network of vulnerable collaterals. While the underlying molecular mechanisms remain unclear, both genetic and immune factors have been implicated, calling for a multiomics approach to study the complex pathogenesis of the disease. We performed whole exosome sequencing and plasma proteomics on a cohort of twelve patients with well-documented moyamoya angiopathy. In addition, we conducted an in-depth single cell spatial proteomics analysis on an occluded artery retrieved post-mortem from one idiopathic patient. Variants in the major susceptibility gene RNF213 were found in three patients, while five patients had other underlying genetic conditions, including trisomy 21 and pathogenic variants in ACTA2, SAMHD1 and NFIA. Plasma proteomics revealed cellular fibronectin as a potential biomarker for moyamoya disease, while artery spatial proteomics profiling showed extensive vascular smooth muscle cell infiltration in the intima associated with phenotypic switching. Moreover, infiltration of macrophages and antigen-presenting cells points to a role for inflammatory signals in disease progression. Together, our study supports a multiomics approach to unravel the complex pathogenesis of moyamoya disease, demonstrating the relevance of genetic and immune triggers in vascular remodeling and moyamoya disease development.

2025-10-20 | PXD063236 | Pride

Targeted AURKA degradation: Towards new therapeutic agents for neuroblastoma

Project description:Aurora kinase A (AURKA) is a well-established target in neuroblastoma (NB) due to both its catalytic functions during mitosis and its kinase-independent functions, including stabilization of the key oncoprotein MYCN. We present a structure-activity relationship (SAR) study of MK-5108-derived PROTACs against AURKA by exploring different linker lengths and exit vectors on the thalidomide moiety. PROTAC SK2188 induces the most potent AURKA degradation (DC50,24h 3.9 nM, Dmax,24h 89%) and shows an excellent binding and degradation selectivity profile. Treatment of NGP neuroblastoma cells with SK2188 induced concomitant MYCN degradation, high replication stress/DNA damage levels and apoptosis. Moreover, SK2188 significantly outperforms the parent inhibitor MK-5108 in a cell proliferation screen and patient-derived organoids. Furthermore, altering the attachment point of the PEG linker to the 5-position of thalidomide allowed us to identify a potent AURKA degrader with a linker as short as 2 PEG units. With this, our SAR-study provides interesting lead structures for further optimization and validation of AURKA degradation as a potential therapeutic strategy in neuroblastoma

2023-02-27 | PXD040391 | Pride

Determination of the serum miRNA expression profile in human moyamoya disease (MMD)

Project description:Moyamoya disease (MMD) is a cerebrovascular disease characterized by progressive stenosis of the intracranial internal carotid arteries and their proximal branches. However, the etiology of this rare disease remains widely unknown. Serum microRNA (miRNA) profiles have been screened to identify novel biomarkers for disease diagnosis and prognosis. Here, we identified important serum miRNAs that might play important roles in contributing to MMD pathogenesis through microarray analysis. 10 MMD patients and 10 controls were consecutively recruited at Shanghai Changhai Hospital. Five-ml venous blood was collected from each participant and separated into serum and cellular fractions. We pooled serum samples from 10 MMD patients and 10 controls. Agilent Human 8 x 60K miRNA Array was performed on the two pooled samples.

2013-04-04 | E-GEOD-45737 | biostudies-arrayexpress

Targeted AURKA degradation: Towards new therapeutic agents for neuroblastoma

2023-02-27 | PXD040389 | Pride

Determination of the serum miRNA expression profile in human moyamoya disease (MMD)

2013-04-04 | GSE45737 | GEO

HNF4α contributes to hepatic CAR dysfunction in polymicrobial sepsis

Project description:Constitutive androstane receptor (CAR) is a xenobiotic nuclear receptor mainly expressed in the liver, where it regulates drug metabolism and energy homeostasis. CAR has emerged as a promising therapeutic target for diabetes, fatty liver disease, and alcoholic liver disease, but it has not been investigated in the context of sepsis. Here, we show that sepsis impairs CAR function in the liver, partly due to reduced transcription mediated by HNF4α, the key liver identity transcription factor, and partly due to decreased DNA binding, caused by chromatin remodeling, also mediated by HNF4α. This impairment leads to the downregulation of several genes and proteins involved in monocarboxylic acid, fatty acid, and xenobiotic metabolism, contributing to increased sepsis lethality, and is associated with an elevated hepatic acute phase response. LC-MSMS analysis was used to identify the proteins differentially expressed in the liver 24h after sepsis onset.

2025-09-15 | PXD062961 | Pride

CCR1 inhibition sensitizes multiple myeloma cells to glucocorticoid therapy

Project description:One of the cornerstone drugs in the treatment of multiple myeloma (MM) are glucocorticoids. Because MM cells hijack the bone marrow microenvironment to obtain growth and survival signals, resistance to glucocorticoid-induced apoptosis emerges, yet, the underlying mechanisms remain poorly characterized. Here we identify that the chemokine receptor CCR1 together with its main ligand CCL3, plays a pivotal role in reducing glucocorticoid sensitivity of MM cells. We show that blocking of CCR1 signalling with the antagonist BX471 enhances the anti-MM effects of the glucorticoid dexamethasone in several MM cell lines, primary patient material and in a myeloma xenograft mouse model. Mechanistically, the drug combination shifts the balance between pro- and antiapoptotic proteins towards apoptosis and deregulates lysosomal proteins. We further find that the glucocorticoid-induced downregulation of CCR1 mRNA and protein is blunted in a glucocorticoid-resistance onset model. Finally, we demonstrate that CCR1 inhibition partially reverses GC-resistance, hereby offering a viable glucocorticoid resensitization strategy for MM treatment.

2025-06-18 | PXD055337 | Pride

Effect of glutamine treatment on human brain microvascular endothelial cells

Project description:We found glutamine levels were positively associated with a greater risk of stroke. After treatment with glutamine, HBMECs exhibited enhanced proliferation, migration, and EndMT, all reversed by ITGB4 knockdown. In ITGB4-transfected HBMECs, the MAPK-ERK-TGF-β/BMP pathway was activated, with Smad4 knockdown reversing the EndMT. Furthermore, atorvastatin suppressed the EndMT by inhibiting Smad1/5 phosphorylation and promoting Smad4 ubiquitination in ITGB4-transfected HBMECs. Finally, ITGB4 upregulation was confirmed in the superficial temporal arteries of patients with moyamoya.

2024-05-01 | GSE259423 | GEO

Vagus Nerve Stimulation enhances remyelination and decreases innate neuroinflammation in a Multiple Sclerosis rodent model.

Project description:This study investigated the effect of Vagus Nerve Stimulation (VNS) on innate neuroinflammation and remyelination in lysolecithin (LPC) induced demyelination, a preclinical model for Multiple Sclerosis (MS). In a first experiment (demyelination experiment), LPC was injected in the corpus callosum of 33 Lewis rats, inducing a demyelinated lesion, and rats were treated with either continuously-cycled VNS (cVNS) or one-minute per day VNS (1minVNS) or sham VNS, from two days before the injection until three days post-injection (dpi), when they were killed for immunohistochemistry and proteomics analysis. This timepoint corresponded with a demyelinated lesion and peak inflammation. In a second experiment (remyelination experiment), 13 rats were analogously treated with either cVNS or sham from two days before LPC injection until 11 dpi, when they were killed for tissue prelevation for immunohistochemistry and proteomics. This timepoints corresponded with partial remyelination of the lesion. For proteomics analysis, 20 rats were randomly selected, namely five cVNS and five sham rats of the demyelination experiment, and five cVNS and five sham rats of the remyelination experiment.

2024-05-10 | PXD050858 | Pride

Loss of soluble guanylate cyclase, the major nitric oxide receptor, leads to moyamoya and achalasia.

Project description:Background: Moyamoya is a cerebrovascular condition of unknown mechanism characterized by a progressive stenosis of the terminal part of the internal carotid arteries (ICA) and the compensatory development of abnormal “moyamoya” vessels. It leads to ischemic and hemorrhagic stroke. We describe a novel autosomal recessive disease leading to severe moyamoya and early onset achalasia and report its cause in 3 unrelated families. Methods: We used a combination of genetic linkage and exome sequencing in 2 consanguineous to identify rare shared variants. Sanger sequencing of GUCY1A3, the sole gene mutated in both families, was then conducted in the third family. Platelets from one of the patients and controls were used to carry out functional studies. Results: Homozygous mutations of GUCY1A3 gene encoding the alpha1 subunit of soluble guanylate cyclase (sGC), the major receptor for Nitric Oxide (NO), were identified in all 3 families. Platelet analysis showed a complete loss of the mutated protein and showed an unexpected stimulatory role of sGC within platelets. Conclusion: The NO/sGC/cGMP pathway is a major pathway controlling vascular smooth muscle (VSMC) relaxation, vascular tone and vascular remodeling. Our data suggest that alterations of this pathway may lead to an abnormal vascular remodeling process in sensitive vascular areas with low blood

2014-06-19 | GSE48099 | GEO